TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CONCEPT: Comparison of Oxaliplatin vs Conventional Methods With Calcium/Magnesium in First-Line Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.~Inclusion Criteria:~* Histologically or cytologically documented metastatic, measurable adenocarcinoma of the colon, rectum, or appendix with no prior therapies for metastatic disease~* ECOG performance status (PS) of 0 or 1~* Adequate hematologic, renal, and hepatic function as defined by required baseline laboratory parameters~* No other serious concomitant disease.~Exclusion Criteria:~* Peripheral neuropathy \> Grade 1 at baseline~* History of significant cerebrovascular, cardiovascular, or peripheral vascular disease~* Uncontrolled hypertension (defined as blood pressure \> 150/100 mmHg)~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess, within 6 months prior to start of study drug~* Minor surgical procedure, fine needle aspiration, or core biopsy within 7 days prior to start of study drug~* Serious, non-healing wound, ulcer, or bone fracture~* Active gastroduodenal ulcer~* Evidence of bleeding diathesis or coagulopathy~* Significant history of bleeding within 6 months prior to registration~* Prior history of hypertensive crisis or hypertensive encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Manikin Training on Airtraq Avant Learning Curve in Predicted Difficult Airways

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* anesthesia providers (i.e., anesthesia residents, anesthetists, and staff anesthesiologists)~Exclusion Criteria:~* \< 18 years of age~* non-english speaking~* unwilling to sign a study consent form~* related financially or otherwise to the Airtraq Avant manufacturer will not be eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Inservice Training Only (Type: ACTIVE_COMPARATOR): Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
- Inservice and Manikin Training (Type: EXPERIMENTAL): Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Esophageal Absorption in EoE

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 and 80 with eosinophilic esophagitis diagnosed by a combination of compatible symptoms, endoscopic findings, histology, and lack of response to proton pump inhibitors or negative pH study~* endoscopy with esophageal and duodenal biopsies within two weeks of performance of this study~* Patients between the ages of 18 and 80 with eosinophilic esophagitis diagnosed by a combination of compatible symptoms, endoscopic findings, histology, and lack of response to proton pump inhibitors or negative pH study, and are now in histologic remission( \<15phf) by the use of steroids or the six food elimination diet.~* Volunteers will be selected for not having any history of esophageal symptoms~Exclusion Criteria:~* Vulnerable populations, such as those with diminished mental acuity, will be excluded.~* Patients taking Nsaids within 48 hours of the d-xylose testing~* artificial sweeteners within 48 hours of the d-xylose testing~* History of IBD~* Currently smoking or history of smoking~* History of Celiac disease~* Bacterial overgrowth,~* motility disorders~* other diffuse small bowel diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- D-xylose, water, honey (Type: EXPERIMENTAL): * 25 grams of D-xylose~* 10 cc of water~* 2 teaspoons of honey

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study Matching Intraperitoneal Onlay Mesh (IPOM) and Sublay Mesh to Treat Umbilical Hernia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* informed consent~* patient age: ≥ 18 years~* elective surgery for umbilical hernia~* hernia diameter ≥ 1cm~Exclusion Criteria:~* previous history of median laparotomy~* navel site infection~* contraindication for general anaesthesia~* American Society of Anesthesiologists (ASA) score \>IV~* pregnancy~* cirrhosis of the liver (CHILD B and C) and/or ascites~* cytostatic therapy~* incarcerated hernia~* recurrent hernia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intraperitoneal onlay mesh repair (Type: ACTIVE_COMPARATOR): None
- sublay mesh repair (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The study will include three primary cohorts, with any of the following EBV+ diseases:~   Cohort A - DLBCL, 1) in first or subsequent relapse, not eligible for autologous transplantation following salvage therapy OR 2) relapse following autologous transplantation.~   Cohort B - HL, brentuximab vedotin (BV) treatment failure or unable to tolerate BV.~   Cohort C - PTLD, rituximab treatment failure.~2. Presence of active lymphoma or active PTLD, based on imaging performed within the previous 3 months.~3. Tumor positive for EBV encoded RNA (EBER) based on report from certified laboratory.~4. Absolute lymphocyte count (ALC) \>500/µL~5. Male or female ≥ 12 years of age~6. Weight ≥ 35 kg~7. Eastern Cooperative Oncology Group (ECOG) performance score 0-2, inclusively or Lansky score ≥ 60, as age appropriate~8. Able to understand and comply with the requirements of the study and to provide written informed consent or age appropriate assent for pediatric patients.~Exclusion Criteria:~1. Known central nervous system (CNS) lymphoma~2. Primary refractory HL or DLBCL~3. Bulky disease~4. Relapse or progression following previous autologous EBV specific T cell treatment.~5. Use of systemic corticosteroids \> 0.5 mg/kg/day prednisolone or equivalent does of alternative corticosteroid within 10 days prior to obtaining 200 mL starting material~6. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T cell leukemia virus (HTLV).~7. Patient is pregnant or lactating~8. Systemic fungal, bacterial, viral or other infection that is not controlled~9. Prior allogeneic hematopoietic stem cell transplantation (allo HSCT)~10. Known history of primary immunodeficiency

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- baltaleucel-T (Type: EXPERIMENTAL): Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 20 and 70 years~2. Child-Pugh class A (score 5-6)~3. Single hepatocellular carcinoma~4. Maximal diameter of the tumor from 2 to 4 cm when measured on MRI or CT (The diameter on MRI was measured prior to that on CT)~5. No previous treatment~6. Platelet count \> 80,000/mm3~Exclusion Criteria:~1. HCC abutting main hepatic veins or the first branches of the main portal vein~2. HCC abutting vessels ≥ 0.5 cm

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Hepatic resection (Type: EXPERIMENTAL): Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
- Radiofrequency ablation (Type: EXPERIMENTAL): Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Blood Donation--Immune Sequelae and Recruitment

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed squamous cell carcinoma of the hypopharynx or base of the tongue that is newly diagnosed and considered resectable For hypopharyngeal cancer, total laryngectomy would be required surgery Disease staged by clinical exam, endoscopy, and CT or MRI Stage III that is T2-3 N0-1 M0 Stage IV that is T2-3 N2-3 M0 Measurable or evaluable disease other than pleural effusion, ascites, or disease documented by indirect evidence Closed to patients with cancer of the base of tongue as of 11/15/1998~PATIENT CHARACTERISTICS: Age: Adult Performance status: SWOG 0 or 1 Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times normal AST or ALT no greater than 3 times normal Renal: Creatinine no greater than 2 times normal Creatinine clearance at least 60 mL/min Magnesium normal (supplementation allowed) Other: Average hearing loss in both ears no greater than 40 dB in 50-2,000 Hz range No second malignancy within 5 years except: Adequately treated nonmelanomatous skin cancer Carcinoma in situ of the cervix Stage I/II cancer (other than head/neck) in complete remission Not pregnant or nursing Effective contraception required of fertile patients~PRIOR CONCURRENT THERAPY: No prior therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): induction chemotherapy followed by chemoradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women over 18~* Tissue diagnosis of metastatic colon cancer without operational or radiation therapy options~* No RAS mutation in tumor tissue~* Measurable disease according to RACIST criteria v1.1~* ECOG ( Eastern Cooperative Oncology Group) performance status \<=2~* Life expectancy of over 3 months~* Women of fertility age not pregnant~* Ability to understand and sign and informed consent form to participate in the trial and the ability to perform the treatment and follow up required for participation in the trial~* At least three months progression free time in first line cetuximab treatment~* Disease progression according to RACIST v1.1 for first and second lines~* Third line treatment will be applied no less then 17 weeks following and of first line treatment~Exclusion Criteria:~* RAS mutation carriers, or patients with uncertain metastatic colon cancer diagnosis~* Patients operated two weeks prior to accepting trail drug, or that did not recover from treatment~* Level 3 allergic response to any of trial drugs~* First line cetuximab treatment stopped due to allergic response~* Severe medical or mental diagnosis which might increase the risk in drug administration according to treating physician's discretion~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Metastatic colorectal cancer patients (Type: EXPERIMENTAL): Metastatic colorectal cancer patients receiving third line cetuximab treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-75 years of age~* type 2 diabetes mellitus, treated with stable dose of metformin and sulfonylurea for \>/= 12 weeks prior to screening~* HbA1c 7-10% at screening~* body weight stable (+/-5%) for \>/= 12 weeks prior to screening~* fasting C-peptide \>/=1ng/ml~* treatment-naïve for insulin~Exclusion Criteria:~* diagnosis or history of type 1 diabetes mellitus or secondary forms of diabetes~* acute metabolic diabetic complications or evidence of clinically significant diabetic complications~* clinically symptomatic gastrointestinal disease~* history of chronic pancreatitis or acute idiopathic pancreatitis~* \>3 episodes of severe hypoglycemia within 6 months prior to screening~* miocardial infarcion, unstable angina pectoris, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within 6 months prior to screening~* any treatment with exenatide, exendin analogues, GLP-1 or its analogues

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Humeral Compression/Distraction Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult skeletally mature patients 18 years or older, treated by the Orthopaedic Trauma Service at Tampa General Hospital, and the Trauma Service at St. Louis University Hospital~  * Open or closed displaced humeral shaft fractures (displaced OTA code 12A, B, or C), nonunions or malunions~ * amenable to treatment with an intramedullary nail~Exclusion Criteria:~* Intra-articular extension of the fracture, prohibiting treatment with an intramedullary nail;~* Pathologic fracture~* Retained hardware~* Patients with pacemakers~* Age under 18 years.~* Patients who are prisoners or likely to become prisoners~* Homeless, or those likely to have difficulty making follow-up appointments~* Pregnancy~* Ipsilateral nerve or vascular injuries~* Immunocompromised patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- humeral nail (Type: EXPERIMENTAL): Surgical fixation with a humeral compression/distraction nail.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years old~* English speaking~* Able to provide informed consent~* Scheduled to receive a corticosteroid burst of at least 20 mg prednisone or equivalent for at least 7 days~Exclusion Criteria:~* History of allergic reaction to memantine and/or riluzole~* Pregnant or nursing women~* History of liver disease, myocardial infarction, renal failure, diabetes with poor glycemic control, or other unstable medical condition~* Mental retardation, dementia, or other severe cognitive disorder~* Prior prednisone therapy in the last 14 days~* Current alcohol/substance abuse/dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Memantine (Type: ACTIVE_COMPARATOR): Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
- Placebo (Type: PLACEBO_COMPARATOR): Inactive ingredient matching the active medication in appearance
- Riluzole (Type: ACTIVE_COMPARATOR): Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Deep Venous Thrombosis After Hepatobiliopancreatic Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for elective oncological liver or pancreatic resection~* Age equal or greater than 18 years~* Written informed consent~Exclusion Criteria:~* Preexistent coagulopathy~* History of previous VTE~* benign disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Patients with deep venous thrombosis (Type: None): All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a positive finding will be grouped in arm A
- B: Patients without deep venous thrombosis (Type: None): All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a negative finding will be grouped in arm B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues